4//SEC Filing
KKR Genetic Disorder L.P. 4
Accession 0000899243-19-019173
CIK 0001743881other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 4:30 PM ET
Size
29.8 KB
Accession
0000899243-19-019173
Insider Transaction Report
Form 4
KKR Genetic Disorder L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying)
ROBERTS GEORGE R
10% Owner
Transactions
- Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes)
KKR Group Holdings Corp.
10% Owner
Transactions
- Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying)
KKR Management Holdings Corp
10% Owner
Transactions
- Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes)
KKR Management Holdings L.P.
10% Owner
Transactions
- Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying)
KKR Genetic Disorder GP LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying)
KRAVIS HENRY R
10% Owner
Transactions
- Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes)
KKR Management LLC
10% Owner
Transactions
- Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying)
KKR & Co. L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-07-01+34,253,561→ 34,253,561 total(indirect: See footnotes) - Conversion
Series D Preferred Units
2019-07-01−50,446,451→ 0 total(indirect: See footnotes)→ Common Stock (10,178,954 underlying) - Purchase
Common Stock
2019-07-01$17.00/sh+2,647,100$45,000,700→ 36,900,661 total(indirect: See footnotes) - Conversion
Series B Preferred Units
2019-07-01−81,022,727→ 0 total(indirect: See footnotes)→ Common Stock (15,859,312 underlying) - Conversion
Series C Preferred Units
2019-07-01−36,246,893→ 0 total(indirect: See footnotes)→ Common Stock (8,215,295 underlying)
Footnotes (3)
- [F1]Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.
- [F2]The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
- [F3]Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001780408
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 4:30 PM ET
- Size
- 29.8 KB